Enanta Pharmaceutica ENTA

$7.62 -0.36 (-4.51%)

Valuation

Market cap
222,192,000
Revenue TTM
$65,320,000
Net income TTM
$-81,890,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-125.37%
Debt to equity
0.00

Trading

Volume
457,600
Avg volume
297,610
Day's range
$7.56 – $8.06
Shares out
29,159,000
Stochastic %K
1%
Beta
0.75
Analysts
Strong Buy
Price target
$19.50

Price

Company profile

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; E...

Show more

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 607 0800
Website
https://www.enanta.com
Address
4 Kingsbury Avenue, Watertown, United States

Latest news

No headlines yet.